R-Tech Ueno, Sucampo Pharmaceuticals request arbitration against Takeda Pharmaceutical

NewsGuard 100/100 Score

R-Tech Ueno, Ltd., together with Sucampo Pharmaceuticals, Inc. ("Sucampo") and Sucampo AG ("SAG"), has requested arbitration against Takeda Pharmaceutical Co. Ltd. ("Takeda").

R-Tech Ueno supplies Amitiza (TM) Capsules to Takeda pursuant to agreements with Takeda and Sucampo. On March 12, 2010, Sucampo submitted for filing with the International Court of Arbitration, International Chamber of Commerce, a Request for Arbitration against Takeda. In that Request, Sucampo claimed that Takeda has violated the provisions of the October 29, 2004, Collaboration and License Agreement between Sucampo and Takeda and other applicable duties, and that Takeda's violations have injured Sucampo. Sucampo requested all appropriate relief, including termination of the agreements, damages remedy and so on.

In an Amended and Supplemental Request for Arbitration, R-Tech Ueno has joined in the arbitration proceeding filed by Sucampo, and has claimed, among other things, that Takeda has breached the provisions of the October 29, 2004, Supply Agreement among R-Tech Ueno, Takeda and Sucampo, and that its breaches have injured R-Tech Ueno. R-Tech Ueno has requested all appropriate relief, including termination of the agreements, damages remedy and so on.

R-Tech Ueno is unable to predict at this time the effect of this action on the performance of R-Tech Ueno. An announcement will be made when the effect on the performance is fixed.

SOURCE R-Tech Ueno, Ltd.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study highlights global fertility decline and its implications for the future